Procalamine

Hyperphosphataemia, Communicable Diseases, Dialysis therapy + 4 more
Treatment
3 FDA approvals
6 Active Studies for Procalamine

What is Procalamine

Calcium acetateThe Generic name of this drug
Treatment SummaryValine is an important amino acid that helps with muscle growth and tissue repair. It also has stimulant properties and is used in the production of antibiotics.
ProcalAmineis the brand name
image of different drug pills on a surface
Procalamine Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
ProcalAmine
Calcium acetate
1982
77

Approved as Treatment by the FDA

Calcium acetate, otherwise known as ProcalAmine, is approved by the FDA for 3 uses which include Kidney Failure, Chronic and End-stage Renal Failure (ESRF) .
Kidney Failure, Chronic
Helps manage End-stage Renal Failure (ESRF)
End-stage Renal Failure (ESRF)
Helps manage End-stage Renal Failure (ESRF)
Hyperphosphataemia
Helps manage Hyperphosphataemia

Effectiveness

How Procalamine Affects PatientsL-valine is an essential amino acid, which helps build and repair muscles. It also works to lower blood sugar levels and increase growth hormone production. It is important for children's growth and adults' overall health. When taken as a supplement, it is best to combine it with isoleucine and leucine in the ratio of 2:1:2. Without enough L-valine in your diet, you may experience slowed growth, neurological issues, or anemia. It is used in both the pharmaceutical and food industries.
How Procalamine works in the bodyValine, Leucine and Isoleucine are essential amino acids that humans cannot produce, so they must be consumed in the diet. These three amino acids are broken down in muscles, producing energy that is used to make ATP. All three use the same two enzymes in the first two steps of breakdown, then their pathways diverge. Valine is turned into a glucogenic compound, while Isoleucine is both glucogenic and ketogenic. Leucine is converted into ketogenic compounds. When these pathways are disrupted, it is called Maple Syrup Urine Disease and can lead to mental retardation and poor myelin

When to interrupt dosage

The advocated measure of Procalamine is contingent upon the diagnosed state, which may include amino acid supplementation, Encephalopathies and Uremic Encephalopathy. The amount of dosage also relies on the technique of delivery (e.g. Intravenous or Solution - Intravenous) detailed in the following table.
Condition
Dosage
Administration
Hyperphosphataemia
667.0 mg, , 667.0 mg/mL, 0.839 mg/mg, 0.952 mg/mg, 952.0 mg, 5.95 mg/mL, 450.0 mg, 300.0 mg, 668.0 mg, 0.26 mg/mL, 22.0 mg/mL, 6.67 mg/mg, 44.0 mg/mL
, Oral, Tablet - Oral, Tablet, Capsule - Oral, Capsule, Solution, Solution - Oral, Powder, for solution - Topical, Topical, Powder, for solution, Solution - Topical, Intravenous, Injection, Injection - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Tablet, coated, Tablet, coated - Oral
Kidney
667.0 mg, , 667.0 mg/mL, 0.839 mg/mg, 0.952 mg/mg, 952.0 mg, 5.95 mg/mL, 450.0 mg, 300.0 mg, 668.0 mg, 0.26 mg/mL, 22.0 mg/mL, 6.67 mg/mg, 44.0 mg/mL
, Oral, Tablet - Oral, Tablet, Capsule - Oral, Capsule, Solution, Solution - Oral, Powder, for solution - Topical, Topical, Powder, for solution, Solution - Topical, Intravenous, Injection, Injection - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Tablet, coated, Tablet, coated - Oral
high phosphate levels
667.0 mg, , 667.0 mg/mL, 0.839 mg/mg, 0.952 mg/mg, 952.0 mg, 5.95 mg/mL, 450.0 mg, 300.0 mg, 668.0 mg, 0.26 mg/mL, 22.0 mg/mL, 6.67 mg/mg, 44.0 mg/mL
, Oral, Tablet - Oral, Tablet, Capsule - Oral, Capsule, Solution, Solution - Oral, Powder, for solution - Topical, Topical, Powder, for solution, Solution - Topical, Intravenous, Injection, Injection - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Tablet, coated, Tablet, coated - Oral
Astringent
667.0 mg, , 667.0 mg/mL, 0.839 mg/mg, 0.952 mg/mg, 952.0 mg, 5.95 mg/mL, 450.0 mg, 300.0 mg, 668.0 mg, 0.26 mg/mL, 22.0 mg/mL, 6.67 mg/mg, 44.0 mg/mL
, Oral, Tablet - Oral, Tablet, Capsule - Oral, Capsule, Solution, Solution - Oral, Powder, for solution - Topical, Topical, Powder, for solution, Solution - Topical, Intravenous, Injection, Injection - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Tablet, coated, Tablet, coated - Oral
Communicable Diseases
667.0 mg, , 667.0 mg/mL, 0.839 mg/mg, 0.952 mg/mg, 952.0 mg, 5.95 mg/mL, 450.0 mg, 300.0 mg, 668.0 mg, 0.26 mg/mL, 22.0 mg/mL, 6.67 mg/mg, 44.0 mg/mL
, Oral, Tablet - Oral, Tablet, Capsule - Oral, Capsule, Solution, Solution - Oral, Powder, for solution - Topical, Topical, Powder, for solution, Solution - Topical, Intravenous, Injection, Injection - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Tablet, coated, Tablet, coated - Oral
Dialysis therapy
667.0 mg, , 667.0 mg/mL, 0.839 mg/mg, 0.952 mg/mg, 952.0 mg, 5.95 mg/mL, 450.0 mg, 300.0 mg, 668.0 mg, 0.26 mg/mL, 22.0 mg/mL, 6.67 mg/mg, 44.0 mg/mL
, Oral, Tablet - Oral, Tablet, Capsule - Oral, Capsule, Solution, Solution - Oral, Powder, for solution - Topical, Topical, Powder, for solution, Solution - Topical, Intravenous, Injection, Injection - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Tablet, coated, Tablet, coated - Oral
Kidney Failure, Chronic
667.0 mg, , 667.0 mg/mL, 0.839 mg/mg, 0.952 mg/mg, 952.0 mg, 5.95 mg/mL, 450.0 mg, 300.0 mg, 668.0 mg, 0.26 mg/mL, 22.0 mg/mL, 6.67 mg/mg, 44.0 mg/mL
, Oral, Tablet - Oral, Tablet, Capsule - Oral, Capsule, Solution, Solution - Oral, Powder, for solution - Topical, Topical, Powder, for solution, Solution - Topical, Intravenous, Injection, Injection - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Liquid, Liquid - Intravenous, Solution - Intravenous, Tablet, coated, Tablet, coated - Oral

Warnings

Procalamine Contraindications
Condition
Risk Level
Notes
Hypercalcemia
Do Not Combine
Pulse Frequency
Do Not Combine
There are 20 known major drug interactions with Procalamine.
Common Procalamine Drug Interactions
Drug Name
Risk Level
Description
Technetium Tc-99m oxidronate
Major
Calcium acetate may decrease effectiveness of Technetium Tc-99m oxidronate as a diagnostic agent.
Dobutamine
Minor
The therapeutic efficacy of Dobutamine can be decreased when used in combination with Calcium acetate.
3-Aza-2,3-Dihydrogeranyl Diphosphate
Moderate
Calcium acetate can cause a decrease in the absorption of 3-Aza-2,3-Dihydrogeranyl Diphosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.
Acebutolol
Moderate
The therapeutic efficacy of Acebutolol can be decreased when used in combination with Calcium acetate.
Acetyldigitoxin
Moderate
Calcium acetate may increase the arrhythmogenic and cardiotoxic activities of Acetyldigitoxin.
Procalamine Toxicity & Overdose RiskTaking too much of branched-chain amino acids (BCAAs) can lead to dangerously low blood sugar levels and a higher risk of death in those with ALS.

Procalamine Novel Uses: Which Conditions Have a Clinical Trial Featuring Procalamine?

At present, no active trials are investigating the potential of Procalamine to address Uremic Encephalopathy, Encephalopathies and Hepatic coma.
Condition
Clinical Trials
Trial Phases
high phosphate levels
0 Actively Recruiting
Kidney Failure, Chronic
0 Actively Recruiting
Communicable Diseases
0 Actively Recruiting
Hyperphosphataemia
0 Actively Recruiting
Dialysis therapy
4 Actively Recruiting
Not Applicable, Phase 3, Phase 4
Astringent
0 Actively Recruiting
Kidney
0 Actively Recruiting

Patient Q&A Section about procalamine

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is ProcalAmine used for?

"ProcalAmine is a medication indicated for adults who are mildly catabolic and require short-term parenteral nutrition. It is used to preserve body protein and improve nitrogen balance."

Answered by AI

Is ProcalAmine PPN or TPN?

"ProcalAmine is a mixture of glycerol 3% and amino acid 3% that can be heat sterilized and supplied commercially. This product is used as PPN in some institutions."

Answered by AI

How is ProcalAmine administered?

"ProcalAmine was most commonly administered through central catheters 86% of the time, and through peripheral catheters only 14% of the time. Out of all the cases, the overall mechanical complication rate was 19%. Out of the 36 dogs, metabolic complications that could possibly be associated with ProcalAmine administration were found in 12 of them."

Answered by AI

Is ProcalAmine still available?

"The company has stopped making FreAmine III and ProcalAmine."

Answered by AI

Clinical Trials for Procalamine

Image of London Health Sciences Centre in London, Canada.

Exercise for Dialysis

18 - 79
All Sexes
London, Canada
Patients receiving regular hemodialysis (HD) treatments are at a higher risk of cardiovascular events and death as HD can cause a decrease in the pumping of the heart during treatment called 'stunning'. Intradialytic exercise has emerged as a safe and effective non-drug approach to improve cardiovascular health and is now recommended for patients undergoing HD. It is currently advised that HD patients engage in at least 30 minutes of moderate to vigorous exercise three times per week. This study will evaluate the impact of exercise intensity in the HD population and determine if high impact exercise can offer better protection to the heart against HD-induced myocardial stunning.
Recruiting
Has No Placebo
London Health Sciences CentreChris McIntyre, MBBS DM
Image of Rocky Mountain Kidney Care - Lone Tree in Lone Tree, United States.

AP301 for High Phosphate Levels

Any Age
All Sexes
Lone Tree, CO
The goal of this clinical trial is to learn if AP301 could work in the patients receiving maintenance dialysis with elevated blood phosphate. The main questions it aims to answer are: * Does AP301 lower blood phosphate levels? * Does AP301 works on serum calcium level, calcium times phosphate level, and intact parathyroid hormone level? * What discomfort or medical problem do the patients have when taking AP301? * Does AP301 improve quality of life in Chinese patients? The researchers will compare AP301 to an ineffective comparator (a look-alike substance that contains low dose AP301) to see if AP301 works to treat elevated blood phosphate. In the study, the patients will experience the following stages in a chronicle order: * Stop all using blood phosphate-lowering drugs, * Take AP301 or the comparator three times a day for 8 weeks, * Take AP301 three times a day for 24 weeks, and * Take AP301 or the comparator three times a day for 3 weeks. In the first 32 weeks, the dose of AP301 will be adjusted upwards or downwards based on the patient's blood phosphate level and the study doctor's judgment. If the participant has a blood phosphate level above or below a certain level, they may receive additional treatment to lower the blood phosphate level.
Phase 3
Recruiting
Rocky Mountain Kidney Care - Lone Tree (+18 Sites)Alebund Pharmaceuticals
Have you considered Procalamine clinical trials? We made a collection of clinical trials featuring Procalamine, we think they might fit your search criteria.Go to Trials
Image of Johns Hopkins University in Baltimore, United States.

Communication Tool Training for Kidney Failure

18+
All Sexes
Baltimore, MD
The purpose of this study is to test the effect of the "Best Case/Worse Case" (BC/WC) communication tool on receipt of palliative care and intensity of treatment at the end of life, quality of life, and quality of communication for older patients with end-stage renal disease (ESRD) receiving outpatient care at ten nephrology clinics. The intervention was developed and tested with acute care surgical patients at the University of Wisconsin (UW) and is now being testing to see if the intervention will work in a different setting. The intervention will be tested with 320 older adults who have end-stage renal disease (ESRD) and are receiving care from a nephrologist enrolled in the study. Randomly assigned nephrologists within each site will receive the intervention (training to use the BC/WC tool) or to be in the waitlist control, meaning that they will not be offered BC/WC training until the end of the study, when all participants have been enrolled. Participants will be on follow up with surveys and chart review for up to two years after study enrollment. Caregivers will also be invited to participate and complete surveys.
Waitlist Available
Has No Placebo
Johns Hopkins University (+11 Sites)Jean Kutner, MD
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security